Lucintel Profiles Leaders in Generic Drugs Industry: Global Market Expected to Reach US $335.8 Billion in 2017


   January 1 2013
Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The global generic drugs industry experienced average growth over the last five years and is expected to reach approximately US $335.8 billion in 2017.

Lucintel, a leading global Management Consulting and market research firm, has conducted a competitive analysis of the global generic drugs companies and presents its findings in Top Five Global Generic Drug Companies Performance, Strategies, and Competitive Analysis.” The report provides detailed insight into the performance of the top five generic drug companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.

The fragmented generic drugs industry includes producers of medications whose patent or marketing rights have expired. The industry includes drugs from all therapeutic areas: central nervous system, cardiovascular drugs, oncology drugs, and others. A combination of factors such as technology innovations, patent expiration, aging population, and changing lifestyles substantially affect market dynamics. In this study, Lucintel profiles the following five companies with detailed competitive assessments:
  • Abbott Laboratories                               
  • Mylan Inc.                                                 
  • Novartis AG                                       
  • Teva Pharmaceuticals Ind. Ltd. 
  • Watson Pharmaceuticals Inc
As indicated in Lucintel’s study, the Asia Pacific (APAC) region holds good growth potential. India is expected to play an increasing role in the global economy as demand from a growing population continues to drive consumption for generic drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain the market share for generic drugs.

This study provides industry leaders with a Competitive Benchmarking of the world’s top five generic drug companies. The study provides up-to-date information on the market share, profit margins, capabilities, and business strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis, and insight, critical to the development and implementation of effective marketing and sales plans.

For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk@lucintel.com. Lucintel provides cutting-edge decision support services that facilitate critical decisions with greater speed, insight, and cost efficiency. To learn more, visit www.lucintel.com

Lucintel Corporate Customers

Market Entry, M & A, Opportunity Screening,...

Private Equity Customers

Buy Side Services (target screening, due diligence, ..)

Market Research Reports

Aerospace & Defense [44]
Chemical [100]
Composites & Advanced Materials [99]
Construction & Industrial [40]
Consumer and Retail [78]
Economic Analysis [86]
Energy & Utility [68]
Finance & Services [10]
Healthcare [23]
Media & Entertainment [16]
Metals & Mining [16]
Technology & Telecommunication [44]
Transportation [75]

Customer Quotes

"With more than 20 years experience in the industry, this is the first time we have come across such an extensive market analysis for our industry." Ven Cote, CEO, ZCL

"The insights we gained from Lucintel work helped with our business plan…a wonderful professional job…" Mike Jackson, Stahlin

"The report from Lucintel is useful not only for business planners, but also for the technology officers wanting to create a roadmap …" Dr. Giulio Ranzo, Booz Allen

"The information is so comprehensive, it has allowed us to identify & focus our business development efforts. It saved months of leg-work." Bill Barz, L&L Products

"We bought Lucintel report because it is the best report about our industry…a complete and appropriate analysis." Cesare Andrenacci, Ferretti

Quick Query

Partnership between Jushi USA and Gray Construction ...
Armor Express Awarded Five-Year ID/IQ Hard Armor Contract from U.S. Customs and Border Protection...
Hyundai Files Patent for CFRP Front End...
Velocity Composites Signs Long Term Agreement ...
Johns Manville's Starrov 853 for LFT Reinforcements is Available in Americas and Europe ...

Follow us on